(Q36909333)

17 August 2017

1 reference

title

CNS pharmacokinetics of antifungal agents (English)

1 reference

17 August 2017

1 reference

Shravan Kethireddy

1

1 reference

17 August 2017

David Andes

series ordinal

2

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 August 2007

1 reference

Expert Opinion on Drug Metabolism & Toxicology

17 August 2017

published in

1 reference

17 August 2017

volume

3

1 reference

17 August 2017

issue

4

1 reference

17 August 2017

page(s)

573-581

1 reference

Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections.

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Blood-brain barrier drug targeting: the future of brain drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Blood-brain barrier permeation: molecular parameters governing passive diffusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Pharmacokinetics and pharmacodynamics of antibiotics in meningitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Effect of efflux inhibition on brain uptake of itraconazole in mice infected with Cryptococcus neoformans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Population pharmacokinetics of amphotericin B lipid complex in neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Comparison of amphotericin B and N-D-ornithyl amphotericin B methyl ester in experimental cryptococcal meningitis and Candida albicans endocarditis with pyelonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Antifungal therapy for central nervous system histoplasmosis, using a newly developed intracranial model of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Comparative efficacies of four amphotericin B formulations--Fungizone, amphotec (Amphocil), AmBisome, and Abelcet--against systemic murine aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Efficacy of intravenous liposomal amphotericin B (AmBisome) against coccidioidal meningitis in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Effects of antifungal therapy on inflammation, sterilization, and histology in experimental Candida albicans meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Pharmacological Studies with 5-Fluorocytosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Pharmacokinetics of fluconazole in cerebrospinal fluid and serum of rabbits: validation of an animal model used to measure drug concentrations in cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Fluconazole distribution to the brain: a crossover study in freely-moving rats using in vivo microdialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Fluconazole penetration in cerebral parenchyma in humans at steady state

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Pharmacokinetics of 18F-labeled fluconazole in healthy human subjects by positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Comparison of fluconazole and itraconazole in a rabbit model of coccidioidal meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Comparative efficacies of terbinafine and fluconazole in treatment of experimental coccidioidal meningitis in a rabbit model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Fluconazole, with or without dexamethasone for experimental cryptococcosis: impact of treatment timing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Candidal infection in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated young woman.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Voriconazole: a new triazole antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum ("Ramichloridium mackenziei")

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Efficacy of posaconazole in a murine model of central nervous system aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Posaconazole therapy of disseminated phaeohyphomycosis in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Efficacy of Abelcet and caspofungin, alone or in combination, against CNS aspergillosis in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Efficacy of caspofungin combined with amphotericin B against azole-resistant Candida albicans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Efficacy of caspofungin against central nervous system Aspergillus fumigatus infection in mice determined by TaqMan PCR and CFU methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Efficacy of micafungin alone or in combination against systemic murine aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Experience with caspofungin in the treatment of persistent fungemia in neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Fungal infections of the CNS: treatment strategies for the immunocompromised patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Interaction of common azole antifungals with P glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Pharmacokinetics and tissue penetration of fluconazole in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

Antifungal Activity of 5-Fluorocytosine as Measured by Disk Diffusion Susceptibility Testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.573

21 January 2018

Identifiers

DOI

10.1517/17425255.3.4.573

1 reference

17 August 2017

1 reference